World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
103
Citations
90427
World Ranking
7148
National Ranking
3754

Overview

Richard S. Finn is affiliated with the University of California, Los Angeles in the United States. Their research primarily focuses on the field of medicine, with extensive work in hepatology and oncology.

Their recent publications include:

  • Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma (2020), published in New England Journal of Medicine
  • Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma (2020), published in Journal of Clinical Oncology

Frequent co-authors collaborating with Richard S. Finn include:

  • Masatoshi Kudo
  • Andrew X. Zhu
  • Ann-Lii Cheng
  • Peter R. Galle
  • Josep M. Llovet

They have contributed to various publication venues, notably:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Journal of Hepatology
  • Liver Cancer
  • Cancer Research

Their work spans multiple subfields of medicine including:

  • Hepatology
  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research
  • Epidemiology

Main research topics covered in their publications feature:

  • Hepatocellular Carcinoma Treatment and Prognosis
  • Colorectal Cancer Treatments and Studies
  • Cancer Immunotherapy and Biomarkers
  • Pancreatic and Hepatic Oncology Research
  • Cancer Genomics and Diagnostics
  • Advanced Breast Cancer Therapies
  • Cholangiocarcinoma and Gallbladder Cancer Studies

Best Publications

  • Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

    Masatoshi Kudo;Richard S. Finn;Shukui Qin;Kwang Hyub Han

  • Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

    Richard S Finn;Shukui Qin;Masafumi Ikeda;Peter R Galle

  • Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases

    Jorge A. Marrero;Laura M. Kulik;Claude B. Sirlin;Andrew X. Zhu

  • AASLD guidelines for the treatment of hepatocellular carcinoma

    Julie K. Heimbach;Laura M. Kulik;Richard S. Finn;Claude B. Sirlin

  • Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

    Jordi Bruix;Shukui Qin;Philippe Merle;Alessandro Granito

  • Palbociclib and Letrozole in Advanced Breast Cancer

    Richard S. Finn;Miguel Martin;Hope S. Rugo;Stephen Jones

  • Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.

    Andrew X Zhu;Richard S Finn;Julien Edeline;Stephane Cattan

  • Hepatocellular carcinoma.

    Josep M Llovet;Robin Kate Kelley;Augusto Villanueva;Amit G Singal

  • Immunotherapies for hepatocellular carcinoma.

    Josep M Llovet;Josep M Llovet;Josep M Llovet;Florian Castet;Mathias Heikenwalder;Mala K Maini

  • Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

    Andrew X Zhu;Yoon-Koo Kang;Chia-Jui Yen;Richard S Finn

  • The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

    Richard S Finn;John P Crown;Istvan Lang;Katalin Boer

  • Molecular therapies and precision medicine for hepatocellular carcinoma

    Josep M. Llovet;Josep M. Llovet;Robert Montal;Daniela Sia;Richard S. Finn

  • Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

    Richard S. Finn;Baek-Yeol Ryoo;Philippe Merle;Masatoshi Kudo

  • PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

    Richard S Finn;Judy Dering;Dylan Conklin;Ondrej Kalous

  • Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells

    Gottfried E. Konecny;Mark D. Pegram;Natarajan Venkatesan;Richard Finn

  • Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

    Richard S. Finn;Masafumi Ikeda;Andrew X. Zhu;Max W. Sung

  • Treating cancer with selective CDK4/6 inhibitors

    Ben O'Leary;Richard S. Finn;Nicholas C. Turner;Nicholas C. Turner

  • CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)

    T. Yau;J.W. Park;R.S. Finn;A.-L. Cheng

  • Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma

    Milind Javle;Maeve Lowery;Rachna T. Shroff;Karl Heinz Weiss

  • Advances in targeted therapies for hepatocellular carcinoma in the genomic era

    Josep M. Llovet;Augusto Villanueva;Anja Lachenmayer;Richard S. Finn

Frequent Co-Authors

Masatoshi Kudo
Masatoshi Kudo Kindai University
Andrew X. Zhu
Andrew X. Zhu Harvard University
Josep M. Llovet
Josep M. Llovet University of Barcelona
Peter R. Galle
Peter R. Galle Johannes Gutenberg University of Mainz
Ann-Lii Cheng
Ann-Lii Cheng National Taiwan University
Ronald W. Busuttil
Ronald W. Busuttil University of California, Los Angeles
Hope S. Rugo
Hope S. Rugo University of California, San Francisco
Dennis J. Slamon
Dennis J. Slamon University of California, Los Angeles
Karen A. Gelmon
Karen A. Gelmon University of British Columbia
Véronique Diéras
Véronique Diéras Institute Curie

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

As the healthcare field grows, many students look for flexible and affordable ways to enter or advance their medical careers. Several online degree and certification pathways exist for those interested in alternative roles within healthcare.

For nurses aiming to take on leadership or specialized roles, exploring cheapest dnp programs online can help you earn a Doctor of Nursing Practice (DNP) in a cost-effective way. Pharmacists or aspiring professionals may consider pharmacy school online options, which provide the flexibility to gain essential credentials while managing work or family responsibilities.

If you are interested in the technical and administrative side of healthcare, online schools for health information management offer programs to prepare you for roles that support patient care with vital data management. Alternatively, completing a medical coding certification online can quickly open doors to entry-level positions in hospitals, clinics, or remote billing offices.

Exploring these online pathways can help you find a fulfilling career in healthcare, no matter your background or location.

Best Scientists Citing Richard S. Finn

Trending Scientists

Recently Published Articles